Zealand Pharma A/S (NASDAQ: ZEAL) announced the appointment of Eric Rojas as Vice President and Head of Investor Relations, effective April 15. Rojas will report to Chief Financial Officer Henriette Wennicke and will be based in Massachusetts.

Rojas brings more than 20 years of experience in investor relations and finance, having worked with both US-listed and European-listed companies in the biotechnology and pharmaceutical sectors. He previously held senior positions at Vertex Pharmaceuticals (NASDAQ: VRTX), Stoke Therapeutics (NASDAQ: STOK), and Shire, which was acquired by Takeda for $62 billion.

The Copenhagen-based biotechnology company focuses on medicines for obesity and metabolic health. Zealand Pharma combines more than 25 years of peptide research and development expertise with a proprietary data platform that uses advanced data-driven and artificial intelligence approaches.

The company has developed more than 10 drug candidates that have entered clinical development, with two products reaching the market and three candidates currently in late-stage development. Zealand Pharma maintains collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, the company is headquartered in Copenhagen with a US presence in Boston, Massachusetts. The appointment comes as Zealand Pharma establishes a new research site in Cambridge, Massachusetts.